Searching for Synergy: Chemotherapy and Checkpoint Inhibitors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35323910.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0335.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Continuation of programmed cell death protein 1 (PD-1) inhibitors in combination with chemotherapy did not improve clinical outcomes for patients with non-small cell lung cancer who progressed on prior PD-1/programmed death ligand 1 inhibitor monotherapy. This highlights the need to evaluate the precise mechanisms of resistance to PD-1 axis inhibitors and explore alternative therapeutic strategies to overcome resistance. See related article by Jung et al., p. 2321.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms